Dr Andrew Das travelled to Italy to present his research at the Cancer and Epigenetics Gordon Research Conference last week.
Dr Das' postdoctoral work at the Centre for Free Radical Research has explored the use of ascorbate (vitamin C) as an epigenetic therapy in leukaemia.
His poster, Clinical remission following ascorbate treatment in a case of acute myeloid leukaemia with deletions in TET2 and WT1, focused on molecular investigation of a patient with acute myeloid leukaemia where clinical remission was associated with vitamin C treatment.
Dr Das' attendance at this conference was supported by a CMRF travel grant.